From the *Department of Microbiology and Immunology and †Division of Hematology and Medical Oncology, Department of Medicine, James Graham Brown Cancer Center, University of Louisville, Louisville, KY.
Cancer J. 2013 Nov-Dec;19(6):490-501. doi: 10.1097/PPO.0000000000000006.
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells with suppressive properties that preferentially expand in cancer. Myeloid-derived suppressor cells mainly suppress T-cell proliferation and cytotoxicity, inhibit natural killer cell activation, and induce the differentiation and expansion of regulatory T cells. The wide spectrum of MDSC suppressive activity in cancer and its role in tumor progression have rendered these cells a promising target for effective cancer immunotherapy. In this review we briefly discuss the origin of MDSCs and their main mechanisms of suppression and focus more on the approaches developed up to date targeting of MDSCs in tumor-bearing animals and cancer patients.
髓源性抑制细胞(MDSCs)是一群具有抑制特性的未成熟髓系细胞,在癌症中优先扩增。髓源性抑制细胞主要抑制 T 细胞的增殖和细胞毒性,抑制自然杀伤细胞的激活,并诱导调节性 T 细胞的分化和扩增。MDSC 在癌症中的广泛抑制活性及其在肿瘤进展中的作用,使这些细胞成为癌症免疫治疗的一个有前途的靶点。在这篇综述中,我们简要讨论了 MDSC 的起源及其主要的抑制机制,并更侧重于迄今为止针对荷瘤动物和癌症患者的 MDSC 靶向治疗方法。
Curr Top Med Chem. 2017
Clin Immunol. 2016-10-21
Biochim Biophys Acta. 2016-1
J Immunol. 2009-4-15
Breast Cancer Res Treat. 2013-7-5
Front Immunol. 2025-7-2
Curr Issues Mol Biol. 2024-8-23
Biomedicines. 2023-4-27
FEBS Open Bio. 2022-7
Signal Transduct Target Ther. 2021-7-12
Adv Sci (Weinh). 2020-7-29
J Clin Invest. 2020-12-1
Nat Immunol. 2013-6-30
Clin Genitourin Cancer. 2013-5-24
Ann N Y Acad Sci. 2013-5
Int J Cancer. 2013-4-13